Orum Therapeutics shares fell 29.96% after Bristol Myers Squibb halted development of ORM-6151, costing the biotech $80 million in milestone payments.
Orum Therapeutics shares fell 29.96% after Bristol Myers Squibb halted development of ORM-6151, costing the biotech $80 million in milestone payments.This article was originally published by μμΈκ²½μ .
Read Full Story on Source Site →
